Skip to main content
Fig. 6 | Biomarker Research

Fig. 6

From: Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

Fig. 6

AR-V combination and clinical response in 65 mCRPC patients undergoing ARTA treatment. A Cohort overview. Shown are different subgroups according to CTC and AR-V status. B PSA response. Waterfall plots depicting best PSA responses in patients starting ARTA treatment according to CTC and AR-V status: CTC- (left panel), CTC + /AR-V- (middle panel), CTC + /AR-V + (right panel). The dotted line illustrates the threshold of PSA 50% decline defining a PSA response. Numbers indicate responding patients including percentages. C, D Kaplan–Meier curves indicating PFS (C) and OS (D) according to CTC/AR-FL/AR-V status (left panels) and numbers of AR-Vs in AR-V + patients (right panels). E Comparison of AR-FL and AR-Vs mRNA copy numbers per blood sample (5 ml) in AR-FL + (upper panels) and AR-V + patients (lower panels) regarding PSA response (left panels), PFS (middle panels) and OS (right panels) categorized into responders (R) and non-responders (N). P-values (Mann–Whitney test) are as follows: AR-FL in CTC + PSA50: p = 0.13, PFS: p = 0.49, OS: p < 0.01; AR-Vs in CTC + /AR-FL + /AR-V + PSA50: p = 0.07, PFS: p = 0.81, OS: p = 0.19

Back to article page